Tempus AI (TEM) M&A announcement summary

Deal rationale and strategic fit

• Acquisition integrates advanced MRD technology with an AI-enabled oncology platform, expanding participation in the $20 billion+ MRD market and enhancing personalized cancer care.

• Creates a comprehensive tumor-informed and tumor-naive assay portfolio, leveraging complementary capabilities for innovation and growth.

• Accelerates commercial adoption and test volume growth by utilizing a larger salesforce and established commercial infrastructure.

• Enriches multimodal and proprietary longitudinal data capabilities, supporting new product development and biopharma partnerships.

• Builds on an existing partnership and enables more integrated biomarker and drug development collaborations.

Financial terms and conditions

• Personalis shareholders will receive $16.25 per share, representing a 6% premium to the prior close and a 28% premium to the 30-day VWAP.

• Total transaction value is $1.7 billion ($1.5 billion net of existing ownership), with consideration in stock and up to 50% cash at the acquirer's discretion.

• Maximum exchange ratio is 0.3356, with stock priced at closing; cash portion can be financed with cash on hand, existing credit facilities, or new borrowing.

• Transaction expected to close in late 2026 or early 2027, subject to shareholder and regulatory approvals.

Synergies and expected cost savings

• Integration will enable broader sales force deployment, higher test volumes, and revenue growth as more indications secure reimbursement.

• Enhanced data integration and scale expected to benefit clinical and biopharma businesses, unlocking new value from longitudinal MRD data.

• Combination advances biomarker discovery and accelerates innovation for patients and partners.